Summary & Overview
HCPCS Level II Q4317: Vitograft per square centimeter
HCPCS Level II code Q4317 designates Vitograft billed per square centimeter as an add-on material supplied in addition to a primary surgical procedure. This code identifies a graft material commonly used to support tissue repair, regeneration, or reconstruction during operative care and matters for billing clarity, bundle delineation, and supply-cost management across hospital and ambulatory surgical settings. Key national payers commonly involved in coverage and claims processing for graft materials include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the clinical context for Q4317, how the code is positioned as an add-on supply line, and what to expect in payer interactions and claims submission workflows. The publication covers benchmark metrics, typical billing scenarios, common modifiers used with add-on supply codes, and policy update considerations that affect coverage and payment adjudication. It also highlights typical sites of service and the service line classification for supply/biologic graft materials. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q4317 describes Vitograft billed per square centimeter as an add-on supply or material that is listed separately in addition to a primary procedure. The service type is graft material/supplemental biologic, typically used to augment tissue repair or replacement during surgical procedures. The typical site of service is operating room or other surgical setting where graft materials are applied.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a full-thickness or complex partial-thickness soft tissue wound requiring graft augmentation or scaffold to support dermal regeneration after debridement. Example scenario: a 58-year-old patient with a non-healing lower-extremity ulcer following chronic venous insufficiency and prior failed conservative care presents to an outpatient surgical suite. The wound is measured, photographed, and sharp debridement is performed to remove necrotic tissue and biofilm. Hemostasis is achieved, and the operative team applies an acellular dermal matrix product, billed as Q4317 per square centimeter as an add-on to the primary wound procedure. The product is fenestrated or trimmed to fit the wound bed and secured with sutures or adhesive dressings. Post-application wound care instructions and a plan for staged dressing changes and follow-up visits are documented. Typical sites of service include outpatient hospital-based ambulatory surgery centers, hospital operating rooms, and specialized wound care centers. The service type is skin graft/dermal matrix application (add-on material) billed in addition to the primary surgical debridement or grafting procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity is substantially greater than typical for the primary procedure that the dermal matrix augments. |